ReviewEuropean journal of medical research2022
Potential therapeutic options for COVID-19: an update on current evidence.
Review in European journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.
- Epigenetic changes in patients with post-acute COVID-19 symptoms (PACS) and long-COVID: A systematic review.Expert reviews in molecular medicine · 2024Pooled it
- Efficacy and safety of combined nebulization of unfractionated heparin, acetylcysteine, budesonide and ipratropium bromide in hospitalised patients with COVID-19 pneumonia: a randomized controlled clinical trial.BMC pulmonary medicine · 2025Trial
- Trial
- Inhibitors Targeting SARS-CoV-2 Papain-Like Protease: Screening, Design, Synthesis, and Biological Evaluation.ChemMedChem · 2026Article
- Clinical Evolution of a Cohort of Patients with COVID-19 Treated with Usual Medical Care Plus Polymerized Type I Collagen During the Pandemic Emergency.Medical sciences (Basel, Switzerland) · 2026Article
- Remdesivir in COVID-19: pros and cons.Frontiers in pharmacology · 2026Review
- Background rates of medical events of interest before and during the COVID-19 pandemic: a longitudinal cohort study using claims data.BMJ open · 2025Article
- Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.Molecular therapy. Nucleic acids · 2025Review
- Hemoperfusion Combined With Continuous Renal Replacement Therapy in the Management of ARDS COVID-19 Patients: A Quasi-Experimental Study.Health science reports · 2025Article
- Anti-interferon armamentarium of human coronaviruses.Cellular and molecular life sciences : CMLS · 2025Review
- The relationship between microRNAs and COVID-19 complications.Non-coding RNA research · 2025Review
- Single-cell Technology in Stem Cell Research.Current stem cell research & therapy · 2025Review
- Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions.PloS one · 2025Article
- Article
- An in-depth exploration of snake venom-derived molecules for drug discovery in advancing antiviral therapeutics.Heliyon · 2024Review
- Article
- Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19.Inflammopharmacology · 2024Article
- Review
- Impact of COVID-19 on antibiotic usage in primary care: a retrospective analysis.Scientific reports · 2024Article
- Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects.World journal of stem cells · 2024Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19 pandemic and is a major public health concern nowadays. The rapid and global spread of this coronavirus leads to an increase in hospitalizations and thousands of deaths in many countries. To date, great efforts have been made worldwide for the efficient management of this crisis, but there is still no effective and specific treatment for COVID-19. The primary therapies to treat the disease are antivirals, anti-inflammatories and respiratory therapy. In addition, antibody therapies currently have been a many active and essential part of SARS-CoV-2 infection treatment. Ongoing trials are proposed different therapeutic options including various drugs, convalescent plasma therapy, monoclonal antibodies, immunoglobulin therapy, and cell therapy. The present study summarized current evidence of these therapeutic approaches to assess their efficacy and safety for COVID-19 treatment. We tried to provide comprehensive information about the available potential therapeutic approaches against COVID-19 to support researchers and physicians in any current and future progress in treating COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.